Wednesday, August 17, 2022 2:45:33 PM
https://www.niaid.nih.gov/diseases-conditions/monkeypox-treatment
https://www.globenewswire.com/en/news-release/2022/03/03/2396703/9738/en/SIGA-Reports-Financial-Results-for-Three-and-Twelve-Months-Ended-December-31-2021.html
One might think tecovirimat's 2021 U.S. sales of $113M are unimpressive, but consider that , the last natural outbreak of smallpox in the United States occurred in 1949 and, further that the WHO declared smallpox eradicated in 1980
In 2021 the U.S. bought $113M worth of NIAID developed tecovirimat and Canada bought $12M. Clearly, these countries are stockpiling this drug, which indicates to me, that they believe "eradicated" really means eradicated for now.
Tecovirimat is also a good example of what happens after NIAID takes a drug successfully to a Phase 2A. The company that owns the drug completes the rest of the development through FDA approval/authorization.
In the case of B-AV, Leo will be in the driver's seat, not only because "B" will have the data. thanks to NIAID. but also because the potential partner will know that after a successful Phase 3 and FDA approval/authorization: the U.S. gov't, as well as other gov'ts will be the first customers in line placing orders in the hundreds of millions for B-AV (broad spectrum), B-COVID, Monkeypox or any other family of viruses that threaten the U.S. and other populations around the world.
It is very important that NIAID has latched onto Brilacidin and after 2.5 years is still investigating the scope of its antiviral attributes. NIAID's is responsible for finding and initially developing vaccines and therapeutics that address viral pathogens that are threatening or could threaten the U.S. population. NIAID is the playmaker, who coordinates and collaborates with other similarly concerned U.S. gov't agencies and gov't-funded, private research institutions.
NIAID has a high-degree of interest in Brilacidin and I can't wait to see which direction they move in. Will it be "B" as a COVID prophylactic, broad-spectrum antiviral or possibly something involving mokeypox?
One thing's for sure, the antiviral sector is Brilacidin's most lucrative area ($67B) and IPIX is in collaboration with an agency of the U.S. government (NIAID) that is extremely interested in investigating "B" ,as an antiviral, for all that it can do. AT NO CHARGE TO IPIX.
NIAID, operating in its own interest with Brilacidin, could be a very, very, financially rewarding collaboration for IPIX. This is what NIAID's drug development track record suggest.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM